Benzinga

Benzinga

Benzinga

sábado, agosto 29

Kyverna Therapeutics Inc

KYTXNASDAQ
Trade with Public
Trade with Public
$8.37
-0.27-3.13%
al cierre: Aug 28, 5:00 PM EST
$8.53
0.161.91%
After hour: 4:11 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Kyverna Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kyverna Therapeutics (KYTX).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingOverweight# Analysts6Avg. Consensus PT$22Upside to Avg. PT+154.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 3, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedBuy$25
May 15, 2026HC Wainwright & Co.Mitchell S. KapoorPT RaiseBuy$20→$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $25 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the price target from $20 to $25.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Kyverna Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and maintains $20 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $31 to $33.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25

Morgan Stanley analyst Michael Ulz maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $20 to $25.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved